Ovarian tissue and oocyte cryopreservation

doi:10.1016/j.fertnstert.2006.08.083

Cited by 31 publications

(3 citation statements)

References 43 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It avoids the necessity for ovarian stimulation and stores a substantial amount of ovarian tissue [1,2]. Cryopreservation of ovarian tissue is feasible to restore fertility for young women requiring urgent treatment for cancer and is even the only option to preserve fertility in children with cancer [3].…”

Section: Introductionmentioning

confidence: 99%

VEGF and FGF2 Improve Revascularization, Survival, and Oocyte Quality of Cryopreserved, Subcutaneously-Transplanted Mouse Ovarian Tissues

Hwu

et al. 2016

IJMS

View full text Add to dashboard Cite

This study was conducted to investigate the effect of the vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2) on revascularization, survival, and oocyte quality of cryopreserved, subcutaneously-transplanted mouse ovarian tissue. Autologous subcutaneous transplantation of vitrified-thawed mouse ovarian tissues treated with (experimental group) or without (control group) VEGF and FGF2 was performed. After transplantation to the inguinal region for two or three weeks, graft survival, angiogenesis, follicle development, and oocyte quality were examined after gonadotropin administration. VEGF coupled with FGF2 (VEGF/FGF2) promoted revascularization and significantly increased the survival rate of subcutaneously-transplanted cryopreserved ovarian tissues compared with untreated controls. The two growth factors did not show long-term effects on the ovarian grafts. In contrast to the untreated ovarian grafts, active folliculogenesis was revealed as the number of follicles at various stages and of mature oocytes in antral follicles after gonadotropin administration were remarkably higher in the VEGF/FGF2-treated groups. Although the fertilization rate was similar between the VEGF/FGF2 and control groups, the oocyte quality was much better in the VEGF/FGF2-treated grafts as demonstrated by the higher ratio of blastocyst development. Introducing angiogenic factors, such as VEGF and FGF2, may be a promising strategy to improve revascularization, survival, and oocyte quality of cryopreserved, subcutaneously-transplanted mouse ovarian tissue.

show abstract

Section: Introductionmentioning

confidence: 99%

VEGF and FGF2 Improve Revascularization, Survival, and Oocyte Quality of Cryopreserved, Subcutaneously-Transplanted Mouse Ovarian Tissues

Hwu

et al. 2016

IJMS

View full text Add to dashboard Cite

show abstract

“…In some patients, hormonal therapy and treatment with gonadotropin releasing hormone (GnRH) agonists during chemotherapy has demonstrated ovarian protection by preventing ovulation, yet may be medically-inadvisable in hormone-sensitive cancers. Ovarian stimulation with cryopreservation of oocytes or embryos can be less ideal because of delay in initiation of cancer treatment, but it remains a promising clinical technique with substantial pregnancy rates that continues to improve with advancement of reproductive technology [ 5 ]. It is a preferred method in that it permits natural fertility using fresh or frozen and thawed ovarian cortex, but ischemic changes and loss of primordial follicles are two major complications that can occur [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Preservation of Fertility in Female Cancer Patients Desiring Future Child Bearing; What is Available and What can be Offered

Husseinzadeh

2013

World J Oncol

View full text Add to dashboard Cite

The aim of this review is to present an overview of available methods for preservation of ovarian function and fertility in female cancer patients who desire to maintain their child-bearing capacity for future pregnancies. A Medline search was conducted. Published articles from American and European studies from 1976 to present were reviewed. The effect of cancer treatment on the ovary, as well as different methods of fertility preservation and their reproductive outcomes are presented. Pregnancy rates vary according to the type of primary malignancy, stage of disease, method of fertility preservation (for example, hormonal therapy, cryopreservation, fertility-sparing surgery), and other confounding factors such as the patient’s age, reproductive capacity, status of partnership, and genetic disposition. The highest rates of successful pregnancy were observed with embryo cryopreservation. Today, higher cure rates and longer survival are a result of earlier cancer diagnosis and treatment. In conjunction with the advances in assisted reproduction, the preservation of ovarian function and fertility is a major part of multidisciplinary care that should be offered to any young female patient with cancer. Fertility preservation in young cancer patients raises a number of ethical issues particularly regarding standard versus experimental therapies, and long-term financial cost.

show abstract

“…They should only be performed as experimental procedures under IRB approved protocols and at centers with the necessary expertise. 1,7,10 …”

mentioning

confidence: 99%

Ethical and Psychological Considerations in Fertility Preservation Counseling

Browne

Nurudeen²,

Armstrong³

et al. 2008

The Cancer Journal

View full text Add to dashboard Cite

Ovarian tissue and oocyte cryopreservation

Abstract: Although currently investigational, ovarian tissue cryopreservation and oocyte cryopreservation hold promise for future female fertility preservation, particularly following aggressive chemotherapy and/or radiotherapy treatment protocols.

Cited by 31 publications

References 43 publications

VEGF and FGF2 Improve Revascularization, Survival, and Oocyte Quality of Cryopreserved, Subcutaneously-Transplanted Mouse Ovarian Tissues

VEGF and FGF2 Improve Revascularization, Survival, and Oocyte Quality of Cryopreserved, Subcutaneously-Transplanted Mouse Ovarian Tissues

Preservation of Fertility in Female Cancer Patients Desiring Future Child Bearing; What is Available and What can be Offered

Ethical and Psychological Considerations in Fertility Preservation Counseling

Contact Info

Product

Resources

About